| Methods |
Not double blind, elective regimen,
crossover ‐ 3 months in between treatment arms. |
| Participants |
20 participants (10 male, 10 female), mean age 12.6 years. PsA colonised. 3 drop outs, 17 completed trial. |
| Interventions |
Ceftazidime 150 mg/kg/day, 8‐hourly vs ceftazidime plus tobramycin 10 mg/kg/day, 8‐hourly, 14‐day course. |
| Outcomes |
Lung function, inflammatory markers, development of resistant strains. |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Described as randomised, but no details of method given. |
| Allocation concealment (selection bias) |
Unclear risk |
Not discussed. |
| Blinding (performance bias and detection bias)
All outcomes |
Low risk |
Both interventions given with same volume and in same way. |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
3 participants excluded ‐ reasons given (bacteriological resistance developed between treatment arms in 2 participants and a 3rd withdrew on first day of 2nd treatment arm due to nausea). |
